drugset / Trial / NCT01746771
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
\[Phase I\] The main objective of this study is to evaluate the safety, tolerability and determine the Recommended Dose (RD) of HM781-36B(Poziotinib)combined with Paclitaxel and Trastuzumab \[Phase II\] The main objective of this study is to evaluate anticancer activity through determination of response rate of HM781-36B(Poziotinib)combined with Paclitaxel and Trastuzumab in patients with HER-2 positive advanced gastric cancer
Timeline
- Start
- 2012-11
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Poziotinib | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Background | Trastuzumab | Monoclonal antibody | 8 mg/kg | — |